London, UK, 26 October 2020 – Pulmocide Ltd, which is developing first-in-class inhaled anti-infectives initially for targeted treatment of life-threatening lung infections, is pleased to announce that the company was […]
London, UK, 2 March 2020 – Pulmocide Ltd, which is developing first-in-class inhaled anti-infectives for targeted treatment of life-threatening lung infections, is pleased to announce that company scientists gave 4 […]
02 March 2020
London, UK, 13 August 2019 – Pulmocide Ltd, which is developing first-in-class inhaled anti-infectives for targeted treatment of life-threatening lung infections, is pleased to announce that in vitro data published […]
13 August 2019
Pulmocide Ltd, which is developing first-in-class inhaled anti-infectives for targeted treatment of invasive fungal lung infections, announces the publication of data demonstrating the synergistic antifungal effect of combining topical administration […]
02 July 2019
We are honoured to have been selected to tell our story at the upcoming Respiratory Innovation Summit on May 17! RIS Agenda Pulmocide’s CSO, Dr. Pete Strong will be presenting […]
26 April 2019
Fungal Update Meeting This is the first report describing the use of PC945 treatment for refractory Aspergillus bronchial anastomotic infection and tracheobronchitis in a lung transplant patient. Treatment was highly […]
02 March 2019
A recent publication in Drug Discovery Today by pulmocide scientists provides an in depth review on current approaches to the discovery of new treatments which are administered by the inhaled […]
29 May 2018
Pulmocide presented two posters at the recent 8th Advances Against Aspergillosis Conference, held February 1-3, 2018 in Lisbon, Portugal. There are as follow A full copy of the scientific posters […]
16 February 2018
Pulmocide and PGIMER (Chandigarh, India) presented one poster at the recent 8th Trends in Medical Mycology Conference, held November 6-9, 2017 in Belgrade, Serbia. There are as follow A full […]
16 February 2018
Pulmocide today announces the successful dosing PC945 in a phase 1 study. PC945 is a novel antifungal agent which is delivered by inhaled administration for the treatment of Aspergillus Fumigatus […]
21 November 2017